Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
HW.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.55.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.18.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDK.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LS.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4 (Omicron)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.1.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAY.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.60NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CJ.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HZ.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.69NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.98NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
XBB.1.5.71NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HT.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.90NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
FB.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.18.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.26.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
FK.1.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
CH.1.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.76NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used